中国神经再生研究(英文版) ›› 2020, Vol. 15 ›› Issue (2): 242-250.doi: 10.4103/1673-5374.265544

• 综述:退行性病与再生 • 上一篇    下一篇

干细胞治疗阿尔茨海默病的现状及前景

  

  • 出版日期:2020-02-15 发布日期:2020-05-23
  • 基金资助:
    国家自然科学基金项目(81701076,31670795),2017长白山研究支持基金(440050117010),浙江省药学科学重点学科开放项目(YKFJ2-007),吉林省科学技术厅项目(20190701037GH,20180520138JH,20190701036GH)

Current status and future prospects of stem cell therapy in Alzheimer’s disease

Fu-Qiang Zhang1, Jin-Lan Jiang1, Jing-Tian Zhang2, Han Niu2, Xue-Qi Fu2, Lin-Lin Zeng2   

  1. 1 Scientific Research Centre of China-Japan Union Hospital, Jilin University, Changchun, Jilin Province, China
    2 School of Life Sciences, Jilin University, Changchun, Jilin Province, China
  • Online:2020-02-15 Published:2020-05-23
  • Contact: Xue-Qi Fu, PhD,fxq@jlu.edu.cn; Lin-Lin Zeng, PhD,zenglinlin@jlu.edu.cn.
  • Supported by:
    The work was supported by the National Natural Science Foundation of China, No. 81701076 (to LLZ) and No. 31670795 (to XQF), 2017 Changbai Mountain Research Support Foundation, No. 440050117010 (to XQF), Opening Project of Zhejiang Provincial Top Key Discipline of Pharmaceutical Sciences, No. YKFJ2-007 (to LLZ), grants from the Science and Technology Department of Jilin Province, China, No. 20190701037GH (to FQZ), 20180520138JH (to FQZ), 20190701036GH (to LLZ).

摘要:

阿尔茨海默病是一种常见的进行性神经退行性疾病,其病理特征为存在淀粉样蛋白β斑块和神经原纤维缠结。药物治疗仅能缓解疾病症状,不能治愈疾病,因而会严重影响患者的生活质量。近年来干细胞技术为阿尔茨海默病、帕金森病和肌萎缩侧索硬化等神经退行性疾病的治疗提供了新策略。干细胞的主要来源有神经干细胞、胚胎干细胞、间充质干细胞和诱导多能干细胞。文章讨论了阿尔茨海默病的病理生理学变化、一般治疗,综述了干细胞移植治疗阿尔茨海默病的现状,并分析了干细胞移植治疗阿尔茨海默病临床应用和药物开发所存在的具有套挑战性的未来。

orcid: 0000-0002-8653-9909 (Lin-Lin Zeng)

关键词: 阿尔茨海默病, 淀粉样蛋白β, 药物开发, 神经退行性疾病, 干细胞疗法, 神经干细胞, 胚胎干细胞, 间充质干细胞, 诱导多能干细胞, 神经再生

Abstract: Alzheimer’s disease is a common progressive neurodegenerative disorder, pathologically characterized by the presence of β-amyloid plaques and neurofibrillary tangles. Current treatment approaches using drugs only alleviate the symptoms without curing the disease, which is a serious issue and influences the quality of life of the patients and their caregivers. In recent years, stem cell technology has provided new insights into the treatment of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Currently, the main sources of stem cells include neural stem cells, embryonic stem cells, mesenchymal stem cells, and induced pluripotent stem cells. In this review, we discuss the pathophysiology and general treatment of Alzheimer’s disease, and the current state of stem cell transplantation in the treatment of Alzheimer’s disease. We also assess future challenges in the clinical application and drug development of stem cell transplantation as a treatment for Alzheimer’s disease.

Key words: Alzheimer’s disease, β-amyloid, drug development, embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, nerve regeneration, neural regeneration, neural stem cells, neurodegenerative disorders, stem cell therapy